Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407YS | ISIN: US8162123025 | Ticker-Symbol: 1S70
Frankfurt
31.03.25
08:53 Uhr
12,800 Euro
-0,700
-5,19 %
1-Jahres-Chart
CARTESIAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CARTESIAN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
20,05020,55007:00

Aktuelle News zur CARTESIAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.03.Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics2
17.03.Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright5
13.03.Cartesian Therapeutics GAAP EPS of -$4.49 beats by $1.38, revenue of $38.91M misses by $0.83M3
13.03.Cartesian Therapeutics, Inc. - 10-K, Annual Report1
13.03.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update103Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial...
► Artikel lesen
13.03.Cartesian Therapeutics, Inc. - 8-K, Current Report3
06.03.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant92FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
► Artikel lesen
03.03.Cartesian Therapeutics, Inc. - 8-K, Current Report1
CARTESIAN THERAPEUTICS Aktie jetzt für 0€ handeln
06.02.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants95FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
► Artikel lesen
28.01.Cartesian Therapeutics announces FDA agreement for new trial1
27.01.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis172FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases...
► Artikel lesen
27.01.Cartesian Therapeutics, Inc. - 8-K, Current Report-
13.01.Cartesian Therapeutics, Inc. - 8-K, Current Report3
07.01.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants142FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
► Artikel lesen
26.12.24Cartesian Therapeutics (NASDAQ:RNAC) Stock Price Up 7.2% - Time to Buy?1
23.12.24Cartesian Therapeutics-Direktor Timothy Springer kauft Aktien im Wert von 965.000 US-Dollar2
18.12.24Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants98FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
► Artikel lesen
03.12.24Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial126Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of =3 points...
► Artikel lesen
03.12.24Cartesian Therapeutics, Inc. - 8-K, Current Report-
21.11.24Cartesian Therapeutics, Inc.: Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit6
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1